Sunday, December 26, 2010 3:19:39 PM
No TEVA approval before EOY (as Marth spewed in his recent CC's), but somehow MNTA's stock is still flat as Oklahoma.
How do the other 'affected' companies compare?
SNY: Sanofi's stock is ~7.5% higher than it was mL pre-approval (6 months after approval) (+6.35 billion $'s). Pretty phenomenal in light of their shrinking pipeline and challenges to their business.
TEVA: Teva is essentially flat post mL approval, but that performance is not half bad considering they don't have generic lovenox and now have a threat to Copaxone on the horizon.
NVS: 13% higher than it was pre mL approval. NVS kicking butt and taking names. These guys know how to run a company, and I pray they take MNTA out of its misery sooner rather than later. I'd take a buyout @ $25 right now.
IN summary, MNTA's overall performance is abysmal, and i really think CW / MNTA VP's have spent too much time counting their personal fortunes and not enough on time getting the MNTA message out there.
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM